Dermata Therapeutics Inc (DRMA): basing well at these prices, phase 2 top...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Re: Capitalvaluetrade post# 70

Friday, 05/19/2023 1:12:00 PM

Friday, May 19, 2023 1:12:00 PM

basing well at these prices, phase 2 topline results, phase 3 in june

offering was done in march to fund operations until 2024

Keep Last Read

Replies (1) Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:06:12 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:23 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:00:44 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:00:36 AM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/18/2023 05:15:30 AM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/15/2023 10:00:43 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/07/2023 09:05:59 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:09:02 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:08:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:18:20 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:16:30 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:31:21 PM

InvestorsHub NewsWire

Only $200 per official company press release!